SHANGHAI, Feb. 14, 2013 /PRNewswire/ -- Cellular Biomedicine Group (OTCQB:EBIGD) announced today that it has recently achieved both ISO 9001:2008 certification and ISO-14644 cleanroom certification.
Cellular Biomedicine Group has been accredited the ISO (International Standards Organization) 9001:2008 certification by internationally recognized quality management system SGS and ISO-14644 cleanroom certification from ENV. In working towards this, every operational process within CBMG was analyzed and challenged resulting in a more efficient and agile organization.
ISO 9001:2008 addresses the requirements for implementing an efficient quality management system. This standard ensures that the organization fulfills and achieves continual improvement of its performance in pursuit of the customers’ requirements, applicable regulatory requirements and enhancement of customer satisfaction.
SGS (Societe Generale de Surveillance) the agency granting the ISO 9001:2008 certificate is an international inspection, verification, testing and certification company, recognized as the global benchmark for quality and integrity. The certificate is issued by American National Accreditation Bureau (ANAB). To date CBMG is the only cell therapy company in China to be awarded the ISO 9001:2008 certification by SGS.
In addition, since 2012 CBMG has maintained an ISO-14644 cleanroom certification from ENV Services Inc. ENV is an ISO-accredited, US-based testing and certification company, certified in “Cleanroom Performance Testing” according to NEBB (National Environmental Balancing Bureau). In any precision setting, it is vital that all controlled-environment equipment meet certain design standards to ensure purity, quality and safety. To achieve this goal, the CBMG Shanghai cleanroom facility undergoes a top-to-bottom yearly calibration and validation from ENV.
CBMG President Dr William Cao stated, “We are extremely proud to obtain ISO 9001:2008 and ENV certification, which are important milestones in the development of our company. It is a significant achievement that demonstrates the commitment to a level of excellence upon which our partners can depend. We look forward to announcing additional milestones as we continue to execute on our growth strategy.”
About Cellular Biomedicine Group
Cellular Biomedicine Group, Ltd. develops proprietary cell therapies for the treatment of certain degenerative diseases. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
Contact:
Jeff Ramson
Investor Relations
ProActive Capital Group
646-863-6341
Sarah Kelly
Director of Corporate Communications, CBMG
sarah.kelly@cellbiomedgroup.com
SOURCE Cellular Biomedicine Group
